Legal Representation
Attorney
B. Brett Heavner
USPTO Deadlines
Next Renewal Deadline
2072 days remaining
Section 8 (6-Year) Declaration Due (Based on registration date 2025-03-11)
Due Date
March 11, 2031
Grace Period Ends
September 11, 2031
Additional deadlines exist. Contact your attorney for complete deadline information.
Application History
39 events| Date | Code | Type | Description |
|---|---|---|---|
| Mar 11, 2025 | NRCC | E | NOTICE OF REGISTRATION CONFIRMATION EMAILED |
| Mar 11, 2025 | R.PR | A | REGISTERED-PRINCIPAL REGISTER |
| Feb 20, 2025 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Feb 20, 2025 | ALIE | A | ASSIGNED TO LIE |
| Feb 20, 2025 | SUNA | E | NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED |
| Feb 20, 2025 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Feb 20, 2025 | CNPR | P | ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED |
| Feb 12, 2025 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Nov 23, 2024 | CNRT | W | SU - NON-FINAL ACTION - WRITTEN |
| Nov 23, 2024 | GNRT | O | NON-FINAL ACTION E-MAILED |
| Nov 23, 2024 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Nov 22, 2024 | SUPC | I | STATEMENT OF USE PROCESSING COMPLETE |
| Nov 22, 2024 | DPCC | D | DIVISIONAL PROCESSING COMPLETE |
| Oct 24, 2024 | AITU | A | CASE ASSIGNED TO INTENT TO USE PARALEGAL |
| Aug 20, 2024 | ERTD | I | TEAS REQUEST TO DIVIDE RECEIVED |
| Aug 20, 2024 | EXT3 | S | SOU EXTENSION 3 FILED |
| Aug 20, 2024 | EX3G | S | SOU EXTENSION 3 GRANTED |
| Aug 20, 2024 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Aug 20, 2024 | EISU | I | TEAS STATEMENT OF USE RECEIVED |
| Aug 20, 2024 | EEXT | I | SOU TEAS EXTENSION RECEIVED |
| Aug 20, 2024 | IUAF | S | USE AMENDMENT FILED |
| Aug 20, 2024 | DRRR | I | DIVISIONAL REQUEST RECEIVED |
| Mar 13, 2024 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Mar 12, 2024 | EXT2 | S | SOU EXTENSION 2 FILED |
| Mar 12, 2024 | EEXT | I | SOU TEAS EXTENSION RECEIVED |
| Mar 12, 2024 | EX2G | S | SOU EXTENSION 2 GRANTED |
| Sep 9, 2023 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Sep 7, 2023 | EX1G | S | SOU EXTENSION 1 GRANTED |
| Sep 7, 2023 | EXT1 | S | SOU EXTENSION 1 FILED |
| Sep 7, 2023 | EEXT | I | SOU TEAS EXTENSION RECEIVED |
| Mar 21, 2023 | NOAM | E | NOA E-MAILED - SOU REQUIRED FROM APPLICANT |
| Jan 24, 2023 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Jan 24, 2023 | PUBO | A | PUBLISHED FOR OPPOSITION |
| Jan 4, 2023 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Dec 19, 2022 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Dec 17, 2022 | DOCK | D | ASSIGNED TO EXAMINER |
| Mar 12, 2022 | MDSC | E | NOTICE OF DESIGN SEARCH CODE E-MAILED |
| Mar 11, 2022 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Mar 10, 2022 | NWAP | I | NEW APPLICATION ENTERED |
Detailed Classifications
Class 005
human pharmaceuticals for the treatment of cardiovascular diseases, diseases and conditions associated with cardiac muscle dysfunction, cardiac muscle wasting, cardiac muscle atrophy, cardiac muscle weakness
First Use Anywhere:
Jun 5, 2023
First Use in Commerce:
Jun 5, 2023
Class 042
research in the field of cellular assay screening and pharmaceutical discovery and development
First Use Anywhere:
20150900
First Use in Commerce:
20150900
Additional Information
Design Mark
The mark consists of stylized "C" with a circle between the opening.
Color Claim
Color is not claimed as a feature of the mark.
Classification
International Classes
005
042